BMS-303141
目录号 : GC10884
BMS-303141是一种高效性的可渗透细胞的ATP-柠檬酸裂解酶（ACL）抑制剂，IC50值为0.13μM。
Cas No.:943962-47-8
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
BMS-303141 is a highly potent and cell-permeable ATP-citrate lyase (ACL) inhibitor with an IC50 value of 0.13μM[1]. ACL is a cytosolic enzyme responsible for the production of cytosolic acetyl-CoA, a precursor required for the de novo biosynthesis of cholesterol and fatty acids[2]. BMS-303141 can be used to block glycolytic activity and mitochondrial pyruvate carrier activity[3].
In vitro, treatment of ESCC cells with BMS-303141 (0-80μM) for 24-96h significantly inhibited cell survival and significantly reduced ACLY protein levels in a time- and dose-dependent manner[4]. Pretreatment of HUVEC cells with BMS-303141 (10μM) 4h before LPS stimulation reversed the LPS-induced upregulation of soluble vascular cell adhesion molecule 1 (VCAM-1), soluble E-selectin, and monocyte chemoattractant protein-1 (MCP-1) without affecting cell viability[5].
In vivo, oral administration of BMS-303141 (5mg/kg/day) for 8 days inhibited the growth of liver cancer cells in mice bearing HepG2 cell xenografts. Combination therapy of BMS-303141 and sorafenib significantly reduced tumor volume and weight and inhibited the expression of Ki-67 in tumor tissues[6]. Oral treatment of spontaneous type 2 diabetic mice with BMS-303141 (50mg/kg/day) for 30 days reduced the levels of serum lipids and renal lipogenic enzymes acetyl-CoA carboxylase (ACC), fatty acid synthase (FAS), and HMG-CoA reductase (HMGCR), and alleviated ectopic lipid accumulation (ELA) and inflammation in the kidneys[7].
References:
[1] Li J J, Wang H, Tino J A, et al. 2-hydroxy-N-arylbenzenesulfonamides as ATP-citrate lyase inhibitors[J]. Bioorganic & medicinal chemistry letters, 2007, 17(11): 3208-3211.
[2] Pinkosky S L, Groot P H E, Lalwani N D, et al. Targeting ATP-citrate lyase in hyperlipidemia and metabolic disorders[J]. Trends in molecular medicine, 2017, 23(11): 1047-1063.
[3] Haggadone M D, Speth J, Hong H, et al. ATP Citrate Lyase Links Increases in Glycolytic Flux to Diminished Release of Vesicular Suppressor of Cytokine Signaling 3 by Alveolar Macrophages[M]//TP2. TP002 IMMUNOLOGY AND INFLAMMATION IN PULMONARY INFECTIONS. American Thoracic Society, 2021: A1268-A1268.
[4] Zhang X, Xu Y, Li S, et al. SIRT2‐mediated deacetylation of ACLY promotes the progression of oesophageal squamous cell carcinoma[J]. Journal of Cellular and Molecular Medicine, 2024, 28(6): e18129.
[5] Li R, Meng M, Chen Y, et al. ATP-citrate lyase controls endothelial gluco-lipogenic metabolism and vascular inflammation in sepsis-associated organ injury[J]. Cell Death & Disease, 2023, 14(7): 401.
[6] Zheng Y, Zhou Q, Zhao C, et al. ATP citrate lyase inhibitor triggers endoplasmic reticulum stress to induce hepatocellular carcinoma cell apoptosis via p‐eIF2α/ATF4/CHOP axis[J]. Journal of Cellular and Molecular Medicine, 2021, 25(3): 1468-1479.
[7] Zhan Z, Li A, Zhang W, et al. ATP-citrate lyase inhibitor improves ectopic lipid accumulation in the kidney in a db/db mouse model[J]. Frontiers in Endocrinology, 2022, 13: 914865.
BMS-303141是一种高效性的可渗透细胞的ATP-柠檬酸裂解酶（ACL）抑制剂，IC50值为0.13μM[1]。ACL是一种胞浆酶，负责产生胞浆乙酰辅酶A，乙酰辅酶A是胆固醇和脂肪酸从头生物合成所需的前体[2]。BMS-303141可用于阻断糖酵解活性和线粒体丙酮酸载体活性[3]。
在体外，BMS-303141（0-80μM）处理ESCC细胞24-96h，以时间和剂量依赖性方式显著抑制了细胞存活率，显著降低了ACLY蛋白水平[4]。在LPS刺激前4h用BMS-303141（10μM）预处理HUVEC细胞，逆转了LPS诱导的可溶性血管细胞粘附分子1（VCAM-1）和可溶性E-选择素以及单核细胞趋化蛋白-1（MCP-1）的上调，且不影响细胞活力[5]。
在体内，BMS-303141（5mg/kg/day）通过口服治疗HepG2细胞异种移植小鼠8天，抑制了小鼠的肝癌细胞生长，BMS-303141和索拉非尼联合治疗可显著减小肿瘤体积和重量，抑制了肿瘤组织中Ki-67的表达[6]。BMS-303141（50mg/kg/day）通过口服治疗自发性2型糖尿病小鼠30天，降低了小鼠的血清脂质和肾脏脂肪生成酶乙酰辅酶A羧化酶（ACC）、脂肪酸合酶（FAS）、HMG-CoA还原酶（HMGCR）的水平，减轻了肾脏中的异位脂质积累（ELA）和炎症[7]。
| Cell experiment [1]: | |
Cell lines | ESCC cells |
Preparation Method | ESCC cells were seeded into 96-well plates with 3×103 cells per well and cultured for 24h. They were treated with different concentrations (0, 10, 20, 30, 40, 50, 60, 70, and 80μM) of BMS-303141 or different concentrations (0, 4, 8, 12, 16, and 20μM) of SIRT2 inhibitor AGK2. CCK-8 solution was added at 24, 48, 72, and 96h, and the absorbance at 450nm was measured with a microplate reader 2h later. |
Reaction Conditions | 0, 10, 20, 30, 40, 50, 60, 70, and 80μM; 24, 48, 72, and 96h |
Applications | BMS-303141 significantly inhibited the survival rate of ESCC cells in a time- and dose-dependent manner. |
| Animal experiment [2]: | |
Animal models | BALB/c nude mice |
Preparation Method | HepG2 cells (5×107 cells/mouse) were injected subcutaneously into the abdomen of the forelimb of BALB/c nude mice. When the tumor volume reached 100mm3, they were randomly divided into 4 groups (4 mice in each group) and gavaged with normal saline, BMS-303141, sorafenib, and BMS-303141 combined with sorafenib at the same concentration of tumor suspension at a dose of 5mg/kg/day for 8 consecutive days. After 8 days of treatment, the tumor volume was measured every 2 days. |
Dosage form | 5mg/kg/day for 8 days; p.o. |
Applications | Treatment of BMS-303141 alone inhibited HCC cells. Moreover, combined treatment with BMS-303141 and sorafenib markedly reduced HepG2 tumour volume and weight compared to sorafenib alone group. |
References: [1]Zhang X, Xu Y, Li S, et al. SIRT2‐mediated deacetylation of ACLY promotes the progression of oesophageal squamous cell carcinoma[J]. Journal of Cellular and Molecular Medicine, 2024, 28(6): e18129. [2]Zheng Y, Zhou Q, Zhao C, et al. ATP citrate lyase inhibitor triggers endoplasmic reticulum stress to induce hepatocellular carcinoma cell apoptosis via p‐eIF2α/ATF4/CHOP axis[J]. Journal of Cellular and Molecular Medicine, 2021, 25(3): 1468-1479. | |
| Cas No. | 943962-47-8 | SDF | |
| 化学名 | 3,5-dichloro-2-hydroxy-N-(4-methoxy-[1,1'-biphenyl]-3-yl)benzenesulfonamide | ||
| Canonical SMILES | COC1=C(NS(C2=CC(Cl)=CC(Cl)=C2O)(=O)=O)C=C(C3=CC=CC=C3)C=C1 | ||
| 分子式 | C19H15Cl2NO4S | 分子量 | 424.3 |
| 溶解度 | ≥ 21.2mg/mL in DMSO | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.3568 mL | 11.7841 mL | 23.5682 mL |
| 5 mM | 0.4714 mL | 2.3568 mL | 4.7136 mL |
| 10 mM | 0.2357 mL | 1.1784 mL | 2.3568 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet